UNASSIGNED: This study aimed to review the clinical features and outcome of 53 @entity1 with @entity6872 managed at our Institution between 1976 and 2012. Thirty-five @entity1 had @entity79 and 18 extramedullary @entity6872 . @entity5 sizes were larger in @entity1 with bone involvement (P  =  0  003). Treatment consisted of local radiotherapy (n  =  26), radiotherapy  +  chemotherapy (n  =  15), surgery (n  =  4) and chemotherapy (n  =  8); the local control rate was 94  3%. Progression to multiple @entity1582 was recorded in 20/35 (57  1%) @entity1 with bone involvement and in 1/18 (5  5%) @entity1 with extramedullary disease (P  =  0  0003). The 5-year @entity1349 ( @entity1349 ) rate was 78  4%; @entity79 @entity1 had a significantly worse @entity1349 (71  9% vs. 88  2%, respectively; P  =  0  029) and 5-year progression-free survival (PFS; 53  0% vs. 88  5%; P  =  0  0003) compared to extramedullary @entity6872 @entity1 . On univariate analysis, @entity79 and size (>= 5  cm) impacted negatively on PFS (P  =  0  0027 and P  =  0  04, respectively). @entity79 also affected @entity1349 (P  =  0  04). In multivariate analysis bone location was the only independent prognostic factor for PFS (P  =  0  0041) and @entity1349 (P  =  0  021). @entity1 with @entity79 have a significantly worse prognosis than extramedullary @entity6872 cases.

Clinical features and prognostic factors in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6872 :: ('MESH:D010954', 'Disease') :: ['solitary plasmacytoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumour'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity79 :: ('MESH:D001847', 'Disease') :: ['Bone disease', 'bone disease', 'bone solitary plasmacytoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity6872 :: (MESH:D010954,Disease) :: ['solitary plasmacytoma']
